Faeth Therapeutics

The potential of Artificial Intelligence to accelerate medical discovery is immense, particularly within biology, writes CEO and Co-Founder, Anand Parikh. Unlike the more predictable fields of chemistry and physics, biology presents unique challenges due to its complexity and constant adaptation, areas where AI can play a transformative role but has been limited to date due to this dynamism. Embracing AI in biology means tackling some of the most complex and variable aspects of science for the very first time. By focusing AI’s power on the untapped potential of the metabolic genome in cancer research, for example, we are not just making incremental improvements but are positioned to make quantum leaps in understanding, managing and treating cancer. This is key to unlocking novel strategies that could serve as the fourth pillar of cancer treatment, alongside surgery, chemotherapy, and radiation. This innovative approach could fundamentally transform cancer care, providing personalized, effective treatments based on the metabolic profiling of individual tumors and a patient’s likely reactions to multiple therapeutic approaches. By doing so, we are setting the stage for discoveries that could fundamentally alter our approach to health and disease, making biology the next great frontier for AI. Read more here via Drug Discovery & Development:  https://lnkd.in/gA3A9sgS #CancerResearch #PrecisionMedicine #AIinBiology

Our CEO Anand Parikh will be participating in 1-on-1 investor meetings at the upcoming Jefferies Global Healthcare Conference from June 4-6 in New York. You can schedule a meeting by contacting bridie@faeththerapeutics.com. Faeth is focused on developing therapies targeting cancer metabolism. The role of metabolism in cancer proliferation is well established, yet remains a vastly under-exploited area, with very few cancer metabolism therapies in existence today. Faeth’s differentiated approach to targeting cancer metabolism leverages a systemic understanding of cancer metabolism, functional genomics, and computational biology to develop effective, less toxic therapies. https://lnkd.in/gMzeWZkJ

A great interview with Faeth Therapeutics co-founder Siddhartha Mukherjee with Andrew Dunn at Endpoints News on the doctor-writer worldview, #AI, the future of cancer and the work Faeth just completed in endometrial cancer patients. Faeth just completed a pivotal study using our “PIKTOR” program, which is a combination of inhibition of PI3Kinase and mTOR, along with chemo, in patients that had been heavily pretreated with chemo alone. We saw a strong, pretty unprecedented signal in endometrial cancer patients, and that is what is being followed up. Faeth isn’t a “diet” company, but our mission is to tackle cancer metabolism as a whole. And PIKTOR, which attacks two crucial nodes of cancer metabolism is the best example. I don’t think anyone has seen this sort of a response in endometrial cancer — multiple CRs in heavily pre-treated patients. So it’s a nail-biting time for us. I should say Faeth isn’t JUST a “diet” company. It’s a company that focuses on all aspects of metabolism. Sometimes by changing the metabolic state of a patient (eg. by depletion of a nutrient, or changing metabolic signaling). But the PIKTOR program uses the same principles to attack the cancer cell’s internal metabolic program. https://lnkd.in/g5H4a-AA

Faeth Therapeutics is transforming cancer treatment through metabolic approaches. CEO + Co-Founder Anand Parikh talks about their mission, the metabolic approach to cancer treatment, and the role of technology in the drug discovery process on #NYSEFloorTalk with Judy Khan Shaw.

Thank you NYSE, Judy Khan Shaw and Eric J. Dimise, PhD for hosting Faeth CEO Anand Parikh today to discuss how we are leveraging comprehensive #metabolicdata and #ML to inform a tumor metabolism-focused approach to #cancer treatment.

Our latest study, leveraging insights from metabolic signaling, is giving some patients with cancer a new hope. CEO Anand Parikh tells Abigail Beaney with Clinical Trials Arena, that he has reservations, saying metabolic drugs like GLP1ra’s are unlikely to be effective enough as monotherapies for some indications, but believes there is real promise as combination therapies.  “The concept of metabolic synthetic lethalities, where you hit the genetics of whatever disease you're looking at, but then you use metabolism to block the resistance pathways or the escape pathways. This is going to be a really interesting ticket that I think has applicability, way beyond cancer, rare disease, or inborn errors of metabolism or even cardiometabolic disease,” 🔗 Read the full interview and learn more about the applications of GLP-1’s beyond weight loss. https://lnkd.in/diPpnAcz #canceresearch #clinicaltrials #obesitydrugs

The recent The Wall Street Journal Journal report from Brianna Abbott on the rising toll of uterine cancer is a stark reminder of the urgent need for innovative approaches in the fight against this deadly disease. – Uterine cancer is now the deadliest gynecologic cancer in the U.S., with survival rates declining over the past four decades. – The incidence of uterine cancer is increasing, particularly among Black and Hispanic women, highlighting significant racial disparities in both diagnosis and treatment. – Obesity and rising rates of metabolic diseases are contributing factors to the increase in uterine cancer cases. It is crucial that all women, regardless of race or socioeconomic status, have access to the latest advancements in treatment and early detection. #UterineCancer #CancerResearch #WomensHealth https://lnkd.in/gJKMxPTE

We're honored to announce that our co-founder, Dr. Siddhartha Mukherjee, has been inducted into the prestigious National Academy of Medicine. This distinction underscores Dr. Mukherjee's significant contributions to cancer research and amplifies the dedication of our entire team who are also inducted into the National Academy of Sciences, including our esteemed co-founders Karen Vousden; Dr. Lew Cantley, PhD; Dr. Greg Hannon, PhD; and Dr. Scott Lowe, PhD. As we press forward in our pioneering work in metabolic oncology, this recognition serves as a testament to Faeth Therapeutics' unwavering commitment to scientific excellence and the progression of cancer care. #NationalAcademyOfMedicine #OncologyInnovation #ScientificExcellence #Cancer #Oncology https://lnkd.in/d3ZjrmD6

You can learn more about our newly-appointed Chief Medical Officer, Debbie Chirnomas in this interview with STAT’s ed silverman. 🔗 Read the full interview and get to know the remarkable person contributing to our vision of treating cancer through a combination of therapeutics and metabolic optimization. https://lnkd.in/gkjX8Cph

🚀 We’re excited to announce the appointment of Debbie Chirnomas M.D., M.P.H., as Chief Medical Officer. Dr. Chirnomas will head up the early and late-stage clinical development for Faeth’s #oncology pipeline. #Faeth CEO Anand Parikh said: “Dr. Chirnomas will help the company advance our pipeline of metabolically-driven therapeutics targeting multiple cancers. Debbie comes to Faeth with years of experience in clinical development and medical affairs, which we look to leverage as we continue the clinical development of our lead assets.” Debbie said: “I’m thrilled at the opportunity to help bring the Faeth approach to patients suffering with cancer. We aim to empower patients to participate in their care with a science-based, precision approach to nutrition that will enhance their anti-tumor armamentarium. Faeth is a special company with a pioneering mindset based on outstanding science and is uniquely positioned to bring a radically new approach to cancer therapeutics for at-need patients.” Join us in extending a warm welcome to Dr. Chirnomas! #NewHireAnnouncement